CYCN Logo

Cyclerion Therapeutics, Inc. (CYCN) 

NASDAQ
Market Cap
$4.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
509 of 774
Rank in Industry
273 of 432

Largest Insider Buys in Sector

CYCN Stock Price History Chart

CYCN Stock Performance

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also …

Insider Activity of Cyclerion Therapeutics, Inc.

Over the last 12 months, insiders at Cyclerion Therapeutics, Inc. have bought $0 and sold $0 worth of Cyclerion Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Cyclerion Therapeutics, Inc. have bought $4.37M and sold $77,328 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 961,538 shares for transaction amount of $3M was made by Slate Path Capital LP (10 percent owner) on 2021‑06‑03.

List of Insider Buy and Sell Transactions, Cyclerion Therapeutics, Inc.

2023-08-09Saledirector
8
0.0003%
$3.40$27-10.12%
2021-06-03Purchase10 percent owner
961,538
0.1301%
$3.12$3M-39.01%
2021-06-03PurchaseChief Executive Officer
823,170
0.1171%
$3.28$2.7M-39.01%
2021-06-03Purchasedirector
96,153
0.013%
$3.12$299,997-39.01%
2021-05-06PurchaseChief Executive Officer
302,000
0.0413%
$2.43$733,860+6.43%
2021-05-05PurchaseChief Executive Officer
398,001
0.0553%
$2.53$1.01M+3.92%
2021-05-04PurchaseChief Executive Officer
300,000
0.0415%
$2.29$687,000+14.22%
2021-02-25SaleChief Medical Officer
2,637
0.0004%
$3.99$10,522-24.61%
2021-02-25SaleChief Financial Officer
1,824
0.0003%
$4.00$7,296-24.61%
2020-12-28SalePresident and CSO
20,107
0.0032%
$3.01$60,522+3.68%
2020-11-09PurchaseChief Innovation Officer
125,000
0.0199%
$2.53$316,250+27.42%
2020-11-06SaleChief Financial Officer
3,827
0.0006%
$2.52$9,644+27.42%
2020-02-21SaleChief Financial Officer
3,559
0.0007%
$5.12$18,222-16.49%
2019-12-30SalePresident
25,000
0.0839%
$2.48$62,000+42.59%
2019-12-27SalePresident
25,000
0.0917%
$2.55$63,750+51.97%
2019-11-15PurchaseChief Innovation Officer
125,000
0.4616%
$1.82$227,500+114.44%
2019-11-08SaleChief Financial Officer
3,922
0.0155%
$2.05$8,040+103.16%
2019-04-08Purchasedirector
626,117
0.1105%
$16.00$10.02M-46.83%
2019-04-08Purchasedirector
626,117
0.1105%
$16.00$10.02M-46.83%
2019-04-02PurchasePresident
270,107
0.0504%
$14.81$4M-38.92%

Insider Historical Profitability

6.18%
Slate Path Capital LP10 percent owner
7157601
264.1084%
$1.8410<0.0001%
Hecht Peter MChief Executive Officer
2047698
75.558%
$1.8440<0.0001%
SCHULMAN AMY Wdirector
604482
22.3048%
$1.8410
Busch AndreasChief Innovation Officer
254704
9.3983%
$1.8420+70.93%
Currie Mark GPresident and CSO
251648
9.2856%
$1.8413

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Slate Path Capital LP$1.15M13.21357,8800%+$00.02
Mfn Partners Management Lp$542,272.006.25169,4600%+$00.02
Tyndall Capital Partners L P$527,286.006.08164,777+0.21%+$1,113.60100
Fidelity Investments$519,447.005.99162,327-0.32%-$1,670.40<0.0001
Artal Group S A$444,656.005.13138,9550%+$0<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.